A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Takayasu syndrome
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 30 Nov 2017 Primary endpoint (Time to relapse of Takayasu Arteritis) has not been met as per the results published in the Annals of the Rheumatic Diseases
    • 30 Nov 2017 Results published in the Annals of the Rheumatic Diseases
    • 25 Aug 2017 According to a Chugai Pharmaceuticals media release, based on the results from this and the GiACTA study,the company obtained an approval Actemra 162mg Syringe for subcutaneous (SC) Injection and Actemra 162mg Auto-Injector for SC Injection by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional indications of Takayasu arteritis (TAK) and giant cell arteritis (GCA) that have not responded sufficiently to existing therapies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top